NASDAQ:PYPD

PolyPid - PYPD Stock Forecast, Price & News

$0.75

-0.05 (-6.25%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.72
▼
$0.77
50-Day Range: $0.66
▼
$1.29
52-Week Range: $0.65
▼
$7.75

Volume: 9,652 shs
Average Volume: 37,100 shs
Market Capitalization: $14.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.63

PolyPid MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 1,450.0% Upside
$11.63 Price Target
Short Interest: Healthy
3.60% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.09) to ($0.96) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

255th out of 1,022 stocks

Surgical & Medical Instruments Industry

29th out of 101 stocks

3.4

Analyst's Opinion

Consensus Rating
PolyPid has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.63, PolyPid has a forecasted upside of 1,450.0% from its current price of $0.75.
Amount of Analyst Coverage
PolyPid has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.60% of the float of PolyPid has been sold short.
Short Interest Ratio / Days to Cover
PolyPid has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in PolyPid has recently decreased by 7.75%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
PolyPid does not currently pay a dividend.
Dividend Growth
PolyPid does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PYPD.

2.0

News and Social Media Coverage

News Sentiment
PolyPid has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
Search Interest
Only 1 people have searched for PYPD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

N/A

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PolyPid insiders have not sold or bought any company stock.

1.3

Earnings and Valuation

Earnings Growth
Earnings for PolyPid are expected to grow in the coming year, from ($2.09) to ($0.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PolyPid is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PolyPid is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PolyPid has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About PolyPid (NASDAQ:PYPD) Stock

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

PYPD Stock News Headlines

November 29, 2022 | finance.yahoo.com

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

November 28, 2022 | americanbankingnews.com

PolyPid (NASDAQ:PYPD) & NeuroOne Medical Technologies (NASDAQ:NMTC) Critical Comparison

November 12, 2022 | seekingalpha.com

PolyPid Ltd. (PYPD) Q3 2022 Earnings Call Transcript

November 9, 2022 | finance.yahoo.com

PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results

October 26, 2022 | finance.yahoo.com

PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022

October 20, 2022 | globenewswire.com

PolyPid Announces Cost Reduction Plan - GlobeNewswire

October 20, 2022 | finance.yahoo.com

PolyPid Announces Cost Reduction Plan

October 6, 2022 | nasdaq.com

PolyPid Ltd. Ordinary Shares (PYPD)

September 29, 2022 | streetinsider.com

Best Penny Stocks To Buy Now? 3 To Watch As Stock Market Crash Continues - StreetInsider.com

September 28, 2022 | seekingalpha.com

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU - Seeking Alpha

September 28, 2022 | globenewswire.com

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery - GlobeNewswire

September 28, 2022 | finance.yahoo.com

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

September 19, 2022 | streetinsider.com

PolyPid Ltd. (PYPD) Reports Publication of Phase 2 Clinical Trial Results for D-PLEX - StreetInsider.com

September 19, 2022 | globenewswire.com

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery - GlobeNewswire

September 19, 2022 | finance.yahoo.com

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

September 13, 2022 | seekingalpha.com

Akero, NeuroBo top healthcare gainers; Codiak, Cardiff Oncology lead losers' pack - Seeking Alpha

September 12, 2022 | benzinga.com

PolyPid (NASDAQ:PYPD) – PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European - Benzinga

September 12, 2022 | finance.yahoo.com

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference - Yahoo Finance

September 12, 2022 | finance.yahoo.com

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

September 6, 2022 | benzinga.com

(PYPD) – This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout - Benzinga

September 6, 2022 | finance.yahoo.com

This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout

September 6, 2022 | seekingalpha.com

IVERIC, First Wave top healthcare gainers; Eiger, bioAffinity lead losers' pack - Seeking Alpha

September 4, 2022 | finance.yahoo.com

PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery - Yahoo Finance

September 3, 2022 | benzinga.com

(PYPD) – PolyPid Announces Top-line Results Of Phase 3 SHIELD I Trial Of D-PLEX100 Did Not Achieve Its Pr - Benzinga

September 2, 2022 | benzinga.com

(IMRX), Novavax (NVAX), (PYPD), Vertex Pharmaceuticals (VRTX) – Recap Of Friday’s Biotech Catalysts - End - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

PYPD Company Calendar

Last Earnings: 11/10/2021
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/08/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PYPD
CUSIP: N/A
CIK: 1611842
Web: www.polypid.com
Phone: 908-378-9530
Fax: N/A
Employees: 75
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.63
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $2.50
Forecasted Upside/Downside: +1,450.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -193.77%
Return on Assets: -128.47%

Debt

Debt-to-Equity Ratio: 0.73
Current Ratio: 2.88
Quick Ratio: 2.88

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.11 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 19,550,000
Free Float: N/A
Market Cap: $14.66 million
Optionable: Not Optionable
Beta: 1.29

Key Executives

Ms. Dikla Czaczkes Akselbrad (Age 49)
Chief Exec. Officer
Comp: $417.38k

Ms. Dalit Hazan (Age 51)
Exec. VP of R&D and Clinical & Regulatory Affairs
Comp: $280.56k

Mr. Ori Warshavsky (Age 44)
Chief Operating Officer - US
Comp: $414.44k

Mr. Jonny Missulawin
Sr. VP of Fin.

Evgeny Valdman
Exec. VP of Operations

Dr. Malka Reichart Ph.D.
Scientific Director

Ms. Orna Blum
Legal Counsel

Ms. Rivi Lev-ari
VP of Human Resource

Dr. Jean-Marc Hagai Pharm.D.
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PYPD Stock - Frequently Asked Questions

Should I buy or sell PolyPid stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PYPD shares.
View PYPD analyst ratings or view top-rated stocks.
What is PolyPid's stock price forecast for 2023?: 4 brokers have issued 12-month target prices for PolyPid's stock. Their PYPD share price forecasts range from $2.50 to $25.00. On average, they anticipate the company's share price to reach $11.63 in the next year. This suggests a possible upside of 1,450.0% from the stock's current price.
View analysts price targets for PYPD or view top-rated stocks among Wall Street analysts.
How have PYPD shares performed in 2022?: PolyPid's stock was trading at $5.74 at the start of the year. Since then, PYPD stock has decreased by 86.9% and is now trading at $0.75.
View the best growth stocks for 2022 here.
When is PolyPid's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our PYPD earnings forecast.
How were PolyPid's earnings last quarter?: PolyPid Ltd. (NASDAQ:PYPD) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.13. During the same quarter in the previous year, the business earned ($0.35) earnings per share.
What other stocks do shareholders of PolyPid own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO).

When did PolyPid IPO?: (PYPD) raised $50 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.
What is PolyPid's stock symbol?: PolyPid trades on the NASDAQ under the ticker symbol "PYPD."
Who are PolyPid's major shareholders?: PolyPid's stock is owned by a variety of institutional and retail investors. Top institutional investors include Silverarc Capital Management LLC (0.00%), Raymond James Financial Services Advisors Inc. (0.17%), XR Securities LLC (0.00%), Group One Trading L.P. (0.00%) and Citadel Advisors LLC (0.00%).
How do I buy shares of PolyPid?: Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PolyPid's stock price today?: One share of PYPD stock can currently be purchased for approximately $0.75.
How much money does PolyPid make?: PolyPid (NASDAQ:PYPD) has a market capitalization of $14.66 million. The company earns $-42,600,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.
How can I contact PolyPid?: PolyPid's mailing address is 18 HASIVIM STREET P.O BOX 7126, PETACH TIKVA L3, 4959376. The official website for the company is www.polypid.com. The company can be reached via phone at 908-378-9530 or via email at ir@polypid.com.

This page (NASDAQ:PYPD) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial